N-3-Substituted Imidazoquinazolinones:  Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction

Phosphodiesterase type 5 (PDE5) inhibitors with improved PDE isozyme selectivity relative to sildenafil may result in agents for the treatment of male erectile dysfunction (MED) with a lower incidence of PDE-associated adverse effects. This paper describes the discovery of 14, a PDE5 inhibitor with...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry Vol. 43; no. 7; pp. 1257 - 1263
Main Authors: Rotella, David P, Sun, Zhong, Zhu, Yeheng, Krupinski, John, Pongrac, Ronald, Seliger, Laurie, Normandin, Diane, Macor, John E
Format: Journal Article
Language:English
Published: Washington, DC American Chemical Society 06-04-2000
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Phosphodiesterase type 5 (PDE5) inhibitors with improved PDE isozyme selectivity relative to sildenafil may result in agents for the treatment of male erectile dysfunction (MED) with a lower incidence of PDE-associated adverse effects. This paper describes the discovery of 14, a PDE5 inhibitor with improved potency and selectivity in vitro compared to sildenafil. This compound shows activity in a functional assay of erectile function comparable to that of sildenafil.
Bibliography:ark:/67375/TPS-B2NC834H-9
istex:928CD72B73EF3C393AC27497DDD3B620EE49E383
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-2623
1520-4804
DOI:10.1021/jm000081+